WallStreetZenWallStreetZen

NASDAQ: OMIC
Singular Genomics Systems Inc Stock Forecast, Predictions & Price Target

Analyst price target for OMIC

Based on 2 analysts offering 12 month price targets for Singular Genomics Systems Inc.
Min Forecast
$6.50-18.75%
Avg Forecast
$10.75+34.38%
Max Forecast
$15.00+87.5%

Should I buy or sell OMIC stock?

Based on 2 analysts offering ratings for Singular Genomics Systems Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their OMIC stock forecasts and price targets.

OMIC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-07-09
lockedlocked$00.00+00.00%2024-03-20

1 of 1

Forecast return on equity

Is OMIC forecast to generate an efficient return?
Company
N/A
Industry
15.47%
Market
33.29%

Forecast return on assets

Is OMIC forecast to generate an efficient return on assets?
Company
N/A
Industry
10.45%

OMIC revenue forecast

What is OMIC's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$2.0M-19.68%
Avg 2 year Forecast
$7.2M+189.16%
OMIC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

OMIC revenue growth forecast

How is OMIC forecast to perform vs Medical Instruments & Supplies companies and vs the US market?
Company
-19.68%
Industry
5.38%
Market
14.78%
OMIC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
OMIC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

OMIC vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
OMIC$8.00$10.75+34.38%Hold
NEPH$2.17$5.00+130.41%Buy
EKSO$1.30$6.25+380.77%Strong Buy
MHUA$0.99N/AN/A
MBOT$1.08$7.00+548.15%Buy

Singular Genomics Systems Stock Forecast FAQ

Is Singular Genomics Systems Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: OMIC) stock is to Hold OMIC stock.

Out of 2 analysts, 0 (0%) are recommending OMIC as a Strong Buy, 0 (0%) are recommending OMIC as a Buy, 2 (100%) are recommending OMIC as a Hold, 0 (0%) are recommending OMIC as a Sell, and 0 (0%) are recommending OMIC as a Strong Sell.

If you're new to stock investing, here's how to buy Singular Genomics Systems stock.

What is OMIC's revenue growth forecast for 2024-2025?

(NASDAQ: OMIC) Singular Genomics Systems's forecast annual revenue growth rate of -19.68% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 5.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.78%.

Singular Genomics Systems's revenue in 2024 is $2,490,000.On average, 1 Wall Street analysts forecast OMIC's revenue for 2024 to be $4,939,532, with the lowest OMIC revenue forecast at $4,939,532, and the highest OMIC revenue forecast at $4,939,532.

In 2025, OMIC is forecast to generate $17,782,315 in revenue, with the lowest revenue forecast at $17,782,315 and the highest revenue forecast at $17,782,315.

What is OMIC's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: OMIC) forecast ROA is N/A, which is lower than the forecast US Medical Instruments & Supplies industry average of 10.45%.

What is OMIC's Price Target?

According to 2 Wall Street analysts that have issued a 1 year OMIC price target, the average OMIC price target is $10.75, with the highest OMIC stock price forecast at $15.00 and the lowest OMIC stock price forecast at $6.50.

On average, Wall Street analysts predict that Singular Genomics Systems's share price could reach $10.75 by Jul 9, 2025. The average Singular Genomics Systems stock price prediction forecasts a potential upside of 34.38% from the current OMIC share price of $8.00.

What is OMIC's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: OMIC) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.